SEPIA ACS-TIMI 42

SEPIA-ACS-TIMI 42 evaluated the efficacy and safety of otamixaban, a direct factor Xa inhibitor, in patients with non-ST-elevation acute coronary syndrome.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Sabatine, M. S., Antman, E. M., Widimsky, P., Ebrahim, I. O., Kiss, R. G., Saaiman, A., Polasek, R., Contant, C. F., McCabe, C. H., Braunwald, E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet. 2009;374(9692):787-95. Abstract